CN101282726A - 3，11b-顺-二氢丁苯喹嗪用于治疗亨廷顿病症状的用途 - Google Patents

3，11b-顺-二氢丁苯喹嗪用于治疗亨廷顿病症状的用途 Download PDF

Info

Publication number
CN101282726A
CN101282726A CNA2006800339758A CN200680033975A CN101282726A CN 101282726 A CN101282726 A CN 101282726A CN A2006800339758 A CNA2006800339758 A CN A2006800339758A CN 200680033975 A CN200680033975 A CN 200680033975A CN 101282726 A CN101282726 A CN 101282726A
Authority
CN
China
Prior art keywords
dihydro
isomer
disease
patient
purposes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800339758A
Other languages
English (en)
Chinese (zh)
Inventor
R·特理吉特
T·菲尤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Valeant Laboratories International Bermuda SRL
Original Assignee
Cambridge Laboratories Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Laboratories Ireland Ltd filed Critical Cambridge Laboratories Ireland Ltd
Publication of CN101282726A publication Critical patent/CN101282726A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNA2006800339758A 2005-07-14 2006-07-13 3，11b-顺-二氢丁苯喹嗪用于治疗亨廷顿病症状的用途 Pending CN101282726A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0514501.6A GB0514501D0 (en) 2005-07-14 2005-07-14 Pharmaceutical compounds
GB0514501.6 2005-07-14

Publications (1)

Publication Number Publication Date
CN101282726A true CN101282726A (zh) 2008-10-08

Family

ID=34897233

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800339758A Pending CN101282726A (zh) 2005-07-14 2006-07-13 3，11b-顺-二氢丁苯喹嗪用于治疗亨廷顿病症状的用途

Country Status (23)

Country Link
US (1) US20080319000A1 (enExample)
EP (2) EP2027861B1 (enExample)
JP (1) JP2009501202A (enExample)
KR (1) KR20080030666A (enExample)
CN (1) CN101282726A (enExample)
AT (2) ATE409481T1 (enExample)
AU (1) AU2006268098B2 (enExample)
CA (1) CA2615077A1 (enExample)
CY (1) CY1108653T1 (enExample)
DE (1) DE602006002982D1 (enExample)
DK (1) DK1885363T3 (enExample)
ES (1) ES2314931T3 (enExample)
GB (1) GB0514501D0 (enExample)
HR (1) HRP20080677T3 (enExample)
ME (1) ME01629B (enExample)
NZ (1) NZ565522A (enExample)
PL (1) PL1885363T3 (enExample)
PT (1) PT1885363E (enExample)
RS (1) RS50626B (enExample)
RU (1) RU2409365C2 (enExample)
SI (1) SI1885363T1 (enExample)
WO (1) WO2007007105A1 (enExample)
ZA (1) ZA200800905B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112469410A (zh) * 2018-05-23 2021-03-09 阿德普蒂奥制药有限公司 药物化合物在治疗亨廷顿病中的用途

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2410947B (en) * 2004-02-11 2008-09-17 Cambridge Lab Ltd Pharmaceutical compounds
GB0516168D0 (en) * 2005-08-05 2005-09-14 Cambridge Lab Ireland Ltd Pharmaceutical compounds
CN101553487B (zh) 2006-11-08 2012-06-13 纽罗克里生物科学有限公司 取代的3-异丁基-9,10-二甲氧基-1,3,4,6,7,11b-六氢-2H-吡啶并[2,1-a]异喹啉-2-醇化合物和与其相关的方法
GB0810857D0 (en) * 2008-06-13 2008-07-23 Cambridge Lab Ireland Ltd Pharmaceutical compounds
US20110053866A1 (en) * 2008-08-12 2011-03-03 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
US20120208773A1 (en) * 2008-08-12 2012-08-16 Valeant International (Barbados) Srl Pharmaceutical compositions with tetrabenazine
GB2462611A (en) * 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
GB2463451A (en) * 2008-09-08 2010-03-17 Cambridge Lab 3, 11b cis-dihydrotetrabenazine compounds for use in the treatment of dementia
GB2463283A (en) * 2008-09-08 2010-03-10 Cambridge Lab 3,11b-cis-dihydrotetrabenazine for use in treating asthma
GB2463452A (en) * 2008-09-08 2010-03-17 Cambridge Lab Desmethyl derivatives of tetrabenazine and pharmaceutical compositions thereof
CA2771539A1 (en) * 2009-08-12 2011-02-17 Valeant International (Barbados) Srl Pharmaceutical compositions with tetrabenzine
EP2576552A4 (en) * 2010-06-01 2013-11-13 Aupex Pharmaceutical Inc BENZOQUINOLONE INHIBITORS OF VMAT2
WO2012095548A2 (es) 2011-01-13 2012-07-19 Centro De Investigación Biomédica En Red De Enfermedades Neurodegenerativas (Ciberned) Compuestos para el tratamiento de enfermedades neurodegenerativas
JP7250692B2 (ja) * 2017-04-01 2023-04-03 アデプティオ ファーマシューティカルズ リミテッド 運動障害の治療における使用のためのジヒドロテトラベナジン
GB201705303D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705302D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705306D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705304D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
JP7386544B2 (ja) 2018-04-25 2023-11-27 シンケイ セラピューティクス インコーポレイテッド テトラベナジン経皮送達デバイス
CN114502154A (zh) * 2019-07-16 2022-05-13 拉什大学医学中心 含苯甲酸酯的组合物治疗神经退行性疾病的用途

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3132147A (en) * 1964-05-05
US3314966A (en) * 1967-04-18 Substituted benzo[a]quinolizines
US3009918A (en) * 1961-11-21 Chz ch
US2954382A (en) * 1960-09-27 Xpreparation of hexahydrobenzoquinol-
US2830993A (en) * 1958-04-15 Quinolizine derivatives
US2843591A (en) * 1958-07-15 Method for preparing same
US3209005A (en) * 1965-09-28 Hexahydro-llbh-benzo[a] quinolizines and processes therefor
US3095419A (en) * 1963-06-25 Process for preparing z-oxo-j-
US3159638A (en) * 1964-12-01 Xcha-chj
US3053845A (en) * 1962-09-11 Benzofykedocolines
US3123609A (en) * 1964-03-03 Benzo
US3079395A (en) * 1963-02-26 Novel z-oxq-benzoquinoliaine
US3045021A (en) * 1959-09-24 1962-07-17 Hoffmann La Roche Preparation of substituted 2-oxobenzoquinolizines
GB999092A (en) * 1959-11-24 1965-07-21 Wellcome Found Method for making benzo(a)-quinolizine derivatives
US3375254A (en) * 1961-09-29 1968-03-26 Burroughs Wellcome Co Manufacture of 1, 2, 3, 4, 6, 7-hexahydro-2-oxo-11bh-benzo(a)quinolizines
US3105079A (en) * 1961-12-29 1963-09-24 Pfizer & Co C 10-aminobenzopyridocolines
US3390152A (en) * 1965-10-21 1968-06-25 Abbott Lab 9, 10-alkoxy-3-alkyl-2, 2-(dithiosubstituted)-benzoquinolizines
JPS4836303B1 (enExample) * 1968-12-27 1973-11-02
US3635986A (en) * 1969-12-22 1972-01-18 Miles Lab 2-substituted amino-hexahydrobenzo(a)quinolizines
YU264675A (en) * 1974-10-23 1982-05-31 Chinoin Gyogyszer Es Vegyeszet Process for obtaining benzo (a)-quinolizidine derivatives
GB1513824A (en) * 1975-05-22 1978-06-14 Wyeth John & Brother Ltd 1,3,4,6,7,11b-hexahydro-2h-benzo(a)quinolizine derivative
US4133812A (en) * 1975-11-21 1979-01-09 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. Process for producing benzo (a) quinolizine derivatives
US4304913A (en) * 1978-11-20 1981-12-08 Miles Laboratories, Inc. Trans-2-substituted-amido-hexahydrobenzo [A]quinolizines
US4353656A (en) * 1980-10-14 1982-10-12 Xerox Corporation Moving coil, multiple energy print hammer system including a closed loop servo
US4778054A (en) * 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
GB2178965B (en) * 1985-07-30 1988-08-03 Glaxo Group Ltd Devices for administering medicaments to patients
GB9004781D0 (en) * 1990-03-02 1990-04-25 Glaxo Group Ltd Device
US6087376A (en) * 1997-02-05 2000-07-11 University Of Kentucky Research Foundation Use of lobeline compounds in the treatment of central nervous system diseases and pathologies
FR2794742B1 (fr) * 1999-06-11 2005-06-03 Sanofi Synthelabo Nouveaux derives du benzene, un procede pour leur preparation et les compositions pharmaceutiques les contenant
US6632666B2 (en) * 2000-01-14 2003-10-14 Biolife Solutions, Inc. Normothermic, hypothermic and cryopreservation maintenance and storage of cells, tissues and organs in gel-based media
CA2398446A1 (en) * 2000-04-18 2001-10-25 Agouron Pharmaceuticals, Inc. Pyrazoles for inhibiting protein kinases
EP1638529B1 (en) * 2003-06-16 2016-08-10 ANDRX Pharmaceuticals, LLC. Oral extended-release composition
GB2410947B (en) * 2004-02-11 2008-09-17 Cambridge Lab Ltd Pharmaceutical compounds
WO2006053067A2 (en) * 2004-11-09 2006-05-18 Prestwick Pharmaceuticals, Inc. Combination of amantadine and a tetrabenazine compound for treating hyperkinetic disorders
KR100682506B1 (ko) * 2005-01-18 2007-02-15 (주)젠크로스 프라지콴텔, 또는 이의 염을 포함하는 약학 조성물
GB0516168D0 (en) * 2005-08-05 2005-09-14 Cambridge Lab Ireland Ltd Pharmaceutical compounds
US20110053866A1 (en) * 2008-08-12 2011-03-03 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
GB2462611A (en) * 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
GB2463451A (en) * 2008-09-08 2010-03-17 Cambridge Lab 3, 11b cis-dihydrotetrabenazine compounds for use in the treatment of dementia
GB2463283A (en) * 2008-09-08 2010-03-10 Cambridge Lab 3,11b-cis-dihydrotetrabenazine for use in treating asthma
GB2463452A (en) * 2008-09-08 2010-03-17 Cambridge Lab Desmethyl derivatives of tetrabenazine and pharmaceutical compositions thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112469410A (zh) * 2018-05-23 2021-03-09 阿德普蒂奥制药有限公司 药物化合物在治疗亨廷顿病中的用途

Also Published As

Publication number Publication date
EP1885363B1 (en) 2008-10-01
RU2008105590A (ru) 2009-08-20
US20080319000A1 (en) 2008-12-25
JP2009501202A (ja) 2009-01-15
RS50626B (sr) 2010-06-30
HRP20080677T3 (hr) 2009-02-28
GB0514501D0 (en) 2005-08-24
RU2409365C2 (ru) 2011-01-20
EP2027861A1 (en) 2009-02-25
DE602006002982D1 (de) 2008-11-13
ES2314931T3 (es) 2009-03-16
ZA200800905B (en) 2010-04-28
WO2007007105A1 (en) 2007-01-18
AU2006268098A1 (en) 2007-01-18
CY1108653T1 (el) 2014-04-09
EP1885363A1 (en) 2008-02-13
PT1885363E (pt) 2009-01-08
KR20080030666A (ko) 2008-04-04
DK1885363T3 (da) 2008-12-08
ATE409481T1 (de) 2008-10-15
SI1885363T1 (sl) 2009-02-28
NZ565522A (en) 2010-04-30
AU2006268098B2 (en) 2011-02-17
ATE522215T1 (de) 2011-09-15
PL1885363T3 (pl) 2009-05-29
CA2615077A1 (en) 2007-01-18
HK1111085A1 (en) 2008-08-01
ME01629B (me) 2010-06-30
EP2027861B1 (en) 2011-08-31

Similar Documents

Publication Publication Date Title
CN101282726A (zh) 3，11b-顺-二氢丁苯喹嗪用于治疗亨廷顿病症状的用途
CN100591680C (zh) 二氢丁苯那嗪类及包含它们的药用组合物
EP1855677B1 (en) 3,11b cis dihydrotetrabanezine for the treatment of schizophrenia and other psychoses
WO2010031251A1 (zh) 一类雷帕霉素碳酸酯类似物、其药物组合物及其制备方法和用途
CN101208345A (zh) (s)-n-甲基纳曲酮、其合成方法以及其药物用途
GB2463451A (en) 3, 11b cis-dihydrotetrabenazine compounds for use in the treatment of dementia
ES2317564T3 (es) 3,11b.cis.dihidrotetrabenazina para el tratamiento de enfermedades proliferativas o inflamaciones.
US8119839B2 (en) Carboxylic acid and antidepressant composition containing the same as active ingredient
US20110039877A1 (en) Use of 3, 11b-cis-dihydrotetrabenazine in the treatment of multiple sclerosis and autoimmune myelitis
CA2727561A1 (en) Dihydrotetrabenanzine for the treatment of anxiety
WO2013113294A1 (zh) 一种甾醇类衍生物及其制备方法与应用
Schaefer Pharmaceuticals
HK1111085B (en) Use of 3,11b-cis-dihydrotetrabenazine for the treatment of symptoms of huntington' s disease
HK1121972A (en) Use of 3,11b-cis-dihydrotetrabenazine for the treatment of symptoms of huntington's disease
HK1111083B (en) 3,11b cis dihydrotetrabanezine for the treatment of schizophrenia and other psychoses
KR20070023666A (ko) 디하이드로테트라베나진 및 이를 함유하는 약학 조성물
CN101351205A (zh) 治疗精神分裂症及其它精神病的3,11b-顺式-二氢丁苯那嗪
HK1125575A (en) 3,11b cis dihydrotetrabanezine for the treatment of psychoses
HK1057216B (en) Plant extracts and alkaloids having antitussive activity
HK1111084B (en) 3,11b-cis-dihydrotetrabenazine for the treatment of a proliferative disease or an inflammation

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: BIOVAIL LABORATORY INTERNATIONAL (BARBADOS) CO., L

Free format text: FORMER OWNER: CAMBRIDGE LAB IRELAND LTD.

Effective date: 20100919

C41 Transfer of patent application or patent right or utility model
COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM: DUBLIN, IRELAND TO: BARBADOS ARBADOS

TA01 Transfer of patent application right

Effective date of registration: 20100919

Address after: Barbados

Applicant after: Biovail Lab Internat Barbados SRL

Address before: Dublin, Ireland

Applicant before: Cambridge laboratories (Ireland) Ltd

AD01 Patent right deemed abandoned

Effective date of abandoning: 20081008

C20 Patent right or utility model deemed to be abandoned or is abandoned